Loading...
Apimeds Pharmaceuticals US, Inc
APUS•AMEX
Healthcare
Drug Manufacturers - Specialty & Generic
$1.26
$-0.29(-18.71%)
U.S. Market is Open • 12:41Apimeds Pharmaceuticals US, Inc (APUS) AI-Powered Stock Analysis
See how Apimeds Pharmaceuticals US, Inc scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerApimeds Pharmaceuticals US, Inc (APUS) Stock Overall Grade
Apimeds Pharmaceuticals US, Inc’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Apimeds Pharmaceuticals US, Inc's overall stock rating.
Forecast
C+Score
53/100Financial Growth
C+Score
50/100Fundamental Growth
DScore
36/100Key Ratios
C+Score
55/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
95/100Analyst Consensus
C+Score
50/100Apimeds Pharmaceuticals US, Inc (APUS) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 53/100 (C+), reflecting weak confidence in its potential. Financial Growth (50/100, C+) and Fundamental Growth (36/100, D) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (95/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Apimeds Pharmaceuticals US, Inc stock grade, including financials, comparisons, and forecasts.